News

A recent study confirmed ambroxol's safety in Parkinson disease dementia, showing stabilization of neuropsychiatric symptoms but no cognitive improvement.

Indirect treatment comparisons showed significantly greater or statistically higher improvements in MG-ADL scores with nipocalimab versus other FcRn blockers over 24 weeks.

West Nile virus poses increasing neurologic risks in the US, with new strains emerging and significant health implications for vulnerable populations.

New findings showed that adjunctive VNS therapy led to sustained reductions in generalized tonic-clonic seizure frequency, supporting its long-term efficacy in patients with drug-resistant epilepsy.

The associate professor of psychiatry and human behavior at UC Irvine explored how analyzing specific sleep oscillations may uncover early neurodegenerative changes and guide future therapeutic targets. [WATCH TIME: 4 minutes]

Exablate Neuro is a noninvasive, MRI-guided focused ultrasound technology designed to treat targeted brain areas without incisions or implanted hardware, offering a lower-risk alternative to traditional surgery.

The updated donanemab dosing schedule is aimed at reducing ARIA risk while maintaining efficacy in early Alzheimer treatment to enhance patient safety.

The director of movement disorders at the Banner Sun Health Research Institute discussed distinguishing atypical Parkinsonian disorders early and planning care around their complex symptomatology. [WATCH TIME: 4 minutes]

The chief medical and scientific officer at Harmony Biosciences discussed the pharmacologic rationale and preclinical development of BP1.15205, a novel orexin receptor 2 agonist for hypersomnolence.

A recent survey reveals rimegepant's effectiveness for short-term migraine prevention, highlighting user demographics, triggers, and treatment strategies.

Eptinezumab showed significant efficacy in reducing chronic migraine days in Asian patients, potentially addressing a critical unmet need for effective treatments.

The associate professor of neurology at the Icahn School of Medicine at Mount Sinai detailed how monitoring tools and neuroprotective approaches are evolving for iRBD as research intensifies on its link to Parkinsonian syndromes. [WATCH TIME: 4 minutes]

The professor of neurology at the Miami Miller School of Medicine discussed how the Cognivue Amyloid Risk Measure (CARM) may help predict amyloid presence and informs diagnosis, trial eligibility, and early treatment pathways.

The director of the MedStar Georgetown Headache Center explained why data from trials like TEMPLE help strengthen the argument for CGRP therapies as first-line treatments for migraine. [WATCH TIME: 3 minutes]

Denali Therapeutics advances treatment for Hunter syndrome with FDA's priority review of tividenofusp alfa, targeting brain delivery and improved patient outcomes.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on stroke triage.

Neurology News Network. for the week ending July 5, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 4, 2025.

Laren Becker, MD, PhD, a physician-scientist at Stanford University, discussed how gastrointestinal dysfunction and peripheral dopaminergic activity impact Parkinson disease treatment and progression.

Continuous subcutaneous apomorphine infusion significantly reduces OFF episodes and enhances ON time in Parkinson's disease patients, improving overall health status.

The nurse practitioner in the Center for Movement Disorders & Neurorestoration at the University of Florida discussed a complex case of childhood-onset dystonia treated with DBS. [WATCH TIME: 6 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of June 2025, compiled all into one place by the NeurologyLive® team.

The director of the MedStar Georgetown Headache Center discussed results from the phase 3 TEMPLE trial, which showed improved tolerability and cognitive outcomes with atogepant vs topiramate in episodic migraine. [WATCH TIME: 5 minutes]

Research reveals that delayed-release amantadine significantly reduces Parkinson disease symptoms and medication use, offering patients improved quality of life.

As the first FDA-approved treatment for Alzheimer agitation, brexpiprazole showcased effective symptom relief with a favorable safety profile.

The associate professor of neurology at the Icahn School of Medicine at Mount Sinai explained how his team validated an iRBD actigraphy classifier across new devices and datasets to enhance early, scalable screening for neurodegenerative disease. [WATCH TIME: 5 minutes]

New findings reveal deramiocel's promising long-term benefits for boys with Duchenne muscular dystrophy cardiomyopathy, enhancing cardiac function and muscle performance.